Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-12-11
2007-12-11
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C424S134100, C530S350000, C530S387300
Reexamination Certificate
active
10910531
ABSTRACT:
The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
REFERENCES:
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5521288 (1996-05-01), Linsley et al.
patent: 5580756 (1996-12-01), Linsley et al.
patent: 5637481 (1997-06-01), Ledbetter et al.
patent: 5770197 (1998-06-01), Brady et al.
patent: 5773253 (1998-06-01), Linsley et al.
patent: 5844095 (1998-12-01), Linsley et al.
patent: 5851795 (1998-12-01), Linsley et al.
patent: 5883223 (1999-03-01), Gray
patent: 5885579 (1999-03-01), Brady et al.
patent: 5885796 (1999-03-01), Linsley et al.
patent: 5916560 (1999-06-01), Larsen et al.
patent: 5968510 (1999-10-01), Brady et al.
patent: 5977318 (1999-11-01), Brady et al.
patent: 6090914 (2000-07-01), Linsley et al.
patent: 6113898 (2000-09-01), Anderson et al.
patent: 6352694 (2002-03-01), June et al.
patent: 6444792 (2002-09-01), Gray et al.
patent: 6534055 (2003-03-01), June et al.
patent: 6641809 (2003-11-01), Brady et al.
patent: 6685941 (2004-02-01), Thompson et al.
patent: 6719972 (2004-04-01), Gribben et al.
patent: 6750334 (2004-06-01), Gray et al.
patent: 6830937 (2004-12-01), Linsley et al.
patent: 2001/0053361 (2001-12-01), Thompson et al.
patent: 2002/0031510 (2002-03-01), Larsen et al.
patent: 2002/0039577 (2002-04-01), Todderud et al.
patent: 2002/0115214 (2002-08-01), June et al.
patent: 2002/0182211 (2002-12-01), Bajorath et al.
patent: 2003/0007968 (2003-01-01), Adams et al.
patent: 2003/0022836 (2003-01-01), Larsen et al.
patent: 2003/0083246 (2003-05-01), Cohen et al.
patent: 2003/0219863 (2003-11-01), Peach et al.
patent: 2004/0014171 (2004-01-01), Peach et al.
patent: 2004/0022787 (2004-02-01), Cohen et al.
patent: 2004/0126373 (2004-07-01), Banerjee et al.
patent: WO 90/05541 (1990-05-01), None
patent: WO 93/19767 (1993-10-01), None
patent: WO 94/28912 (1994-12-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 97/28267 (1997-08-01), None
patent: WO 2004/058800 (2004-07-01), None
patent: WO 2004/058944 (2004-07-01), None
Gittenberger et al., Pediatric Research, 2005, 57: 169-176.
Seko et al., Circulation Research, 1998, 82: 613-618.
Paul W., Fundamental Immunology, 1999, pp. 1202-1203 and 1215.
The Merck Manual, 1999, pp. 1654-1655.
Libby, P. et al., “Inflammation and Atherosclerosis”, Circulation, vol. 105, pp. 1135-1143 (2002).
Casscells, W. et al., “Vulnerable Atherosclerotic Plaque”, Circulation, vol. 107, pp. 2072-2075 (2003).
Libby, P. et al., “Novel Inflammatory Markers of Coronary Risk”, Circulation, vol. 100, pp. 1148-1150 (1999).
Ridker, P. et al., “Long-Term Effects of Pravastatin on Plasma Concentration of C-Reactive Protein”, Circulation, vol. 100, pp. 230-235 (1999).
Ridker, P. et al., “Measurement of C-Reactive Protein For The Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events”, The New England Journal of Medicine, vol. 344, pp. 1959-1965 (2001).
Mach, F. et al., “Functional CD40 Ligand is Expressed on Human Vascular Endlothelial Cells, Smooth Muscle Cells, and Macrophages: Implications for CD40-CD40 Ligand Signaling in Atherosclerosis”, Proc. Nat. Acad. Sci. USA, vol. 94, pp. 1931-1936 (1997).
Mach, F. et al., “Reduction of Atherosclerosis In Mice By Inhbition of CD40 Signalling”, Nature, vol. 394, pp. 200-203 (1998).
Andre, P. et al., “Platelet Derived CD40L”, Circulation, vol. 106, pp. 896-899 (2002).
Schonbeck, U. et al., “Soluble CD40L and Cardiovascular Risk in Women”, Circulation, vol. 104, pp. 2266-2268 (2001).
Heeschen, C. et al., “Soluble CD40 Ligand in Acute Coronary Syndromes”, N. Engl. J. Med., vol. 348, pp. 1104-1111 (2003).
Heeschen, C. et al., “Serum Level of the Antiinflammatory Cytokine Interlukin-10 Is An Important Prognostic Determinent in Patients With Acute Coronary Syndromes”, Circulation, vol. 107, pp. 2109-2114 (2003).
Linsley, P. et al., “The Role of the CD28 Receptor During T Cell Responses To Antigen”, Ann. Rev. Immunol., vol. 11, pp. 191-212 (1993).
Mueller, D. et al., “Clonal Expansion Versus Functional Clonal Inactivation”, Ann. Rev. Immunol., vol. 7, pp. 445-480 (1989).
Linsley, P. et al., “Coexpression and Functional Cooperation of CTLA-4 and CD28 on Activated T Lymphocytes”, J. Exp. Med., vol. 176 pp. 1595-1604 (1992).
Tan, P. et al., “Induction of Alloantigen-Specific Hyporesponsiveness In Human T Lymphocytes By Blocking Interaction of CD28 With Its Natural Ligand B7/BB1”, J. Exp. Med.., vol. 177, pp. 165-173 (1993).
Turka, L. et al., “T-Cell Activation By The CD28 Ligand B7 Is Required For Cardiac Allograft Rejection In Vivo”, Proc. Natl. Acad. Sci. USA, vol. 89, pp. 11102-11105 (1992).
Peach, R. et al., “Complementarity Determining Region 1 (CDR1)-and CDR2-Analogous Regions In CTLA-4 and CD28 Determine the Binding to B7-1”, J. Exp. Med., vol. 180, pp. 2049-2058 (1994).
Oaks, M. et al. “A Native Soluble Form of CTLA-4”, Cellullar Immunology, vol. 201, pp. 144-153 (2000).
Freeman, G. et al., “B7. A New Name of the Ig Superfamily With Unique Expression On Activated and Neoplastic B Cells”, The Journal of Immunology, vol. 143, pp. 2714-2722 (1989).
Yokochi, T et al., “B Lymphoblast Antigen (BB-1) Expressed on Epstein-Barr Virus Activated B Cell Blasts, B Lymphoblastoid Cell Lines, and Burkitt's Lymphomas”, The Journal of Immunology, Vo1., 128, No. 2, pp. 823-827 (1982).
Pasceri, V. et al., “A Tale of Two Diseases, Atheroclerosis and Rheumatoid Arthritis”, Circulation, vol. 100, pp. 2124-2126 (1999).
Ross, Russell, “Atherosclerosis—An Inflammatory Disease”, N. Eng. Journal of Med., vol. 340, No. 2, pp. 115-126 (1999).
Jonasson, Lena, “Expression of Class II Transplantation Antigen on Vascular Smooth Muscle Cells in Human Atherosclerosis”, J. Clin. Invest., vol. 76, pp. 125-131 (1985).
Martin, P. et al., “Preincubation of Donor Bone Marrow Cells With a Combination of Murine Monoclonal Anti-T-Cell Antibodies Without Complement Does Not Prevent Graft-Versus-Host Disease . . . ” Journal of Clinical Immunology, vol. 4, No. 1, pp. 18-22 (1984).
Libby, P. et al., “Atherosclerosis: The New View”, Scientific American, (May), pp. 46-55 (2002).
Schwartz, R. et al., “Costimulation of T Lymphocytes: The Role of CD28, CTLA4, and B7/BB1 in Interleukin-2 Production and Immunotherapy”, Cell, vol. 71, pp. 1065-1068 (1992).
Linsley, P. et al., “Human B7-1 (CD80) and B7-2 (CD86) Bind With Similar Avidities but Distinct Kinetics to CD28 and CTLA-4 Receptors” Immunity, vol. 1, pp. 793-801 (1994).
Linsley, P. et al., “Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule”, Science, vol. 257, pp. 792-795 (1992).
Freeman, G. et al., “Cloning of B7-2: A CTL:A4 Counter-Receptor That Costimulates Human T-Cell Proliferation”, Science, vol. 262, pp. 909-911 (1993).
Azuma, M. et al., “B70 Antigen is a Second Ligand for CTLA4 and CD28”, Nature, vol. 366, pp. 76-79 (1993).
Coari, G. et al., “Shoulder Involvement in Rheumatic Diseases. Sonographic Findings”, The Journal of Rheumatology, vo1. 26, pp. 668-673 (1999).
Arbustini, E. et al., “Coronary Atherpsclerotic Plaques With and Without Thrombus in Ischemic Heart Syndromes: A Morphologic, Immunohistochemical, and Biochemical Study”, The American Journal of Cardiology, vol. 68, pp. 36B-50B (1991).
Jonsson, S. et al., “Extent of Inflammation Predicts Cardiovascular Disease and Overall Mortality in Seropositive Rheumatoid Arthritis”, The Journal of Rheumatology, vol. 26, pp. 2562-2571 (1999).
Huittinen, T. et al., “Synergistic Effect of Persistent Chlamydia pneumoniae Infection, Autoimmunity, and Inf
Bristol--Myers Squibb Company
Gambel Phillip
Ouspenski Ilia
Parlet Nickki L.
Sher Audrey F.
LandOfFree
Methods for treating cardiovascular disease using a soluble... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating cardiovascular disease using a soluble..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cardiovascular disease using a soluble... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3886968